347 results about "Lipoprotein" patented technology

A nucleic acid molecule comprising: i) a first nucleic acid comprising a double stranded inhibitory ribonucleic acid (RNA) molecule comprising a sense and an antisense strand designed with reference to a nucleotide sequence comprising a cardiovascular disease associated gene to be silenced and wherein said cardiovascular gene is proprotein convertase subtilisin kexin 9 (PCSK9) there is provided a single stranded deoxyribonucleic acid (DNA) molecule conjugated to the 5’ end of said sense strand; and ii) a second nucleic acid comprising a double stranded inhibitory ribonucleic acid (RNA) molecule comprising a sense and an antisense strand designed with reference to a different cardiovascular disease associated gene to be silenced wherein said cardiovascular gene is lipoprotein (a) (Lp(a)) and wherein there is provided a single stranded deoxyribonucleic acid (DNA) molecule conjugated to the 5’ end of said sense strand wherein the single stranded deoxyribonucleic acid (DNA) molecule is substantially complementary to the single stranded deoxyribonucleic acid (DNA) molecule set forth in i) above and anneals by complementary base pairing to form a double stranded DNA linker that links the first and second double stranded inhibitory ribonucleic acid (RNA) molecules.

The invention relates to a recombinant bacterium for overexpressing uranyl binding protein and application of the recombinant bacterium, and belongs to the technical field of microorganisms. Bacterial outer membrane protein and uranyl binding protein are expressed in host bacteria, and the uranyl binding protein is anchored on an outer membrane of recombinant bacteria through the bacterial outer membrane protein, so that the uranyl binding protein anchored on the bacterial outer membrane can adsorb uranyl ions. Meanwhile, the invention finds that the expression quantity of the uranyl binding protein can be increased by performing fusion expression on the uranyl binding protein by using LPP-OMPA, so that the adsorption effect of uranyl ions is improved. The recombinant bacterium is prepared into a freeze-dried capsule product, and the freeze-dried capsule product can penetrate through a stomach barrier and is accurately delivered to intestinal tracts so as to realize uranyl ion adsorption.

The present invention relates to a use of benzethonium chloride in preparing a drug for improving or treating non-alcoholic fatty liver disease, and relates to the technical field of new uses of products. The present invention discovers for the first time a new use of benzethonium chloride for improving or treating non-alcoholic fatty liver disease. Benzethonium chloride can reduce hepatocyte lipid deposition and regulate hepatocyte lipid metabolism disorder by intervening in a cell lipid deposition model; it can improve liver lipid accumulation in mice caused by lipid metabolism disorder by administering through the digestive tract, and can improve liver coefficient, liver function, hepatic lobular inflammation, and liver fibrosis. The benzethonium chloride of the present invention can be used for the preparation of drugs for improving or treating non-alcoholic fatty liver disease. The benzethonium chloride of the present invention can inhibit the expression of human apolipoprotein C3, thereby reducing the generation of lipids, and is applied to drugs for treating non-alcoholic fatty liver disease, opening up a new use of benzethonium chloride and providing a new drug option for treating non-alcoholic fatty liver disease.

The invention relates to the technical field of in-vitro diagnostic kits, and provides an apolipoprotein E4 detection kit and application thereof. The immunochromatography test paper comprises detection immunochromatography test paper, the detection immunochromatography test paper comprises a bottom plate, a sample pad, a combination pad, an NC membrane and a water absorption pad, the combination pad and the sample pad are sequentially arranged on one side of the NC membrane, and the water absorption pad is arranged on the other side of the NC membrane; the combination pad is marked with gold manganese oxide nanometer developing particles and an apolipoprotein APOE4 monoclonal antibody. According to the technical scheme, the problems of complicated operation, high cost, low detection sensitivity and weak specificity of apolipoprotein E4 detection in related technologies are solved.

A siRNA that inhibits the expression of apolipoprotein C3 is provided. Provided are a small interfering RNA (siRNA) for inhibiting expression of APOC3 in a cell, a vector and a cell comprising a nucleotide encoding the same, and a method for treating a disease or symptom associated with expression of APOC3 in a subject using the siRNA, the vector or the cell.

The invention provides an Auricularia auricula polysaccharide, its application and preparation method thereof, which belong to the technical field of improving polysaccharide. After being degreased, the Auricularia auricula is subjected to preliminary enzymolysis under the effect of helicase, is further subjected to deep enzymolysis under the effect of complex enzyme through synergetic ultrasound-assisted degradation and extraction with H2O2, and is subjected to mixed fermentation by Lactobacillus bulgaricus, Streptococcus thermophilus and Bifidobacterium longum, the obtained fermented Auricularia auricula polysaccharide is subjected to a phosphorylation reaction under the effect of a phosphorylation reagent, and after further deproteinization and decolorization, the obtained fermented Auricularia auricula polysaccharide is chelated with zinc salt to obtain a polysaccharide-zinc compound, and the amount of the extracted Auricularia auricula polysaccharide is improved. The finished product of the invention has the effects of reducing blood sugar and blood fat, regulating total cholesterol and effectively improving HDL cholesterol.

The invention provides application of ancient-Chinese health-preserving essence in preparation of a protein regulating agent, and belongs to the technical field of biological medicines. The invention provides application of an ancient-Chinese health-preserving essence or an ancient-Chinese health-preserving essence extract in preparation of a reagent for regulating protein functions. Protein comprises at least one of NCAM2, NCAM1, MAP2, VGLUT1, CDK5, DCLK1, TUBB3 and apolipoprotein E. The invention also provides an application of the ancient-Chinese health-preserving essence or the ancient-Chinese health-preserving essence extract in preparation of a reagent for regulating protein functions. In ancient and Chinese health preserving essence positive feedback regulation proteins, an important nerve synaptic function network exists and comprises proteins such as NCAM2, NCAM1, MAP2 and the like, and the proteins play an important role in biological processes such as neural development, synaptic shaping, neural signal transmission and the like. In addition, the ancient-Chinese health-preserving essence can regulate the expression of APOE. The application of the invention not only helps to deepen the scientific understanding of the pharmacodynamic effect of the ancient-Chinese health-preserving essence, but also provides a theoretical basis for the modern and precise application of traditional Chinese medicine compounds.

The invention relates to a cardiovascular disease risk assessment system and method. On the basis of fully considering the influence of dimension index information of kidney-related risk factors on the occurrence risk of cardiovascular diseases, heart and kidney metabolic indexes are integrated. And a mathematical model Fine-Gray is used for screening predictive factors by a step-by-step method. On the premise that traditional cardiovascular disease risk factors are reserved, in order to give consideration to the accuracy and easy generalization of risk assessment, prediction factors are simplified through strict calculation and derivation; the method is constructed based on a small amount of clinically ubiquitous detection index information such as age, sex, smoking or not, systolic pressure (SBP), fasting blood glucose (FBG), non-high density lipoprotein cholesterol (non-HDL-C) and estimated glomerular filtration rate (eGFR) as predictive factors. The method has the advantages of simplicity and convenience in operation, less required information and low professional requirement. Meanwhile, the risk of the outcome of various clinical cardiovascular diseases (including CVD, ASCVD and HF) can be evaluated at the same time, and the method can be suitable for various scenes such as primary medical care and clinical diagnosis and treatment.

The present disclosure provides a siRNA for inhibiting the expression of apolipoprotein C3 (ApoC3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences.

The invention discloses an antibody for resisting apolipoprotein E4 (ApoE4) and application of the antibody, and relates to the field of antibodies. The anti-apolipoprotein E4 antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of apolipoprotein E4, and has good affinity or activity.

The invention discloses a monoclonal antibody which only specifically recognizes neutrophil apolipoprotein homodimer HNL / HNL and does not recognize monomer form HNL. The amino acid sequence of a heavy chain variable region of the antibody is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the antibody is as shown in SEQ ID NO.5. The monoclonal antibody realizes accurate, simple and rapid quantification of homodimer form HNL / HNL, promotes wide clinical application of the detection index, accurately distinguishes bacterial infection and virus infection, and reduces unreasonable use of antibiotics.

The invention provides a cardiovascular and cerebrovascular disease risk prediction method and system, and relates to the technical field of data processing.The method comprises the steps that real-time physiological parameters of a target user are obtained, and the real-time physiological parameters comprise the ambulatory blood pressure fluctuation rate, the serum lipoprotein level, the heart rate variability frequency domain index and the sleep apnea hypopnea index; the method comprises the following steps: preprocessing real-time physiological parameters, extracting instantaneous waveform features of blood pressure signals by adopting wavelet transform, and extracting features related to health conditions, including blood pressure level, blood fat level, blood sugar level, electrocardiogram abnormal indexes and cardiac ultrasound abnormal indexes, to form a feature vector set; according to the method, the real-time physiological parameters are acquired, the feature vector set is formed through preprocessing, the krill swarm algorithm is used for optimization, the three-level fusion model is constructed, finally, the cardiovascular and cerebrovascular disease risk degree of the target user is accurately evaluated, early warning information is output, and the accuracy and timeliness of cardiovascular and cerebrovascular disease risk prediction are effectively improved.

The present invention relates to modified apolipoproteins with a targeting body. The targeting body may be, for example, an antibody or antigen-binding fragment that allows for targeting, for example, a specific cell, tissue or organ. The modified apolipoprotein can be used as a carrier for a payload in place of itself or when incorporated into lipid nanoparticles. The modified apolipoproteins may be used to treat or prevent a disease, or target a payload to a specific target site.

The invention discloses a composite antibacterial preparation containing antibacterial peptide and traditional Chinese medicines as well as a preparation method and application of the composite antibacterial preparation, and belongs to the technical field of biological medicines. The antibacterial peptide provided by the invention is a transmembrane protein derived from bacteriophage, and the core function of the antibacterial peptide is that bacterial cell lysis is promoted by destroying a connection structure of a peptidoglycan layer and lipoprotein of a bacterial cell wall, so that an antibacterial effect is achieved. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 3, the antibacterial peptide is combined with traditional Chinese medicines to form a composite antibacterial preparation, and experiments prove that the composite antibacterial preparation has a relatively good antibacterial effect on gram-positive bacteria and gram-negative bacteria and can be applied to the medical field, such as surgical instrument disinfection and drug-resistant bacterial infection treatment; the field of daily chemicals, such as antibacterial hand sanitizers and wound dressings; in the field of agriculture, for example, animal feed additives for preventing and treating intestinal infection have a good market application prospect.

The present invention relates to a fusion protein and a use thereof, the fusion protein comprising: an apolipoprotein or a fragment thereof; and a targeting protein or a fragment thereof. According to a fusion protein of one aspect, it has been identified that a lipid carrier comprising the fusion protein has significantly improved targeting efficacy, and thus an active substance can be effectively delivered to a desired target by using same.

The invention belongs to the technical field of biological detection, and particularly discloses a cardiovascular marker substance control product and a preparation method thereof, the cardiovascular marker substance control product comprises a serum matrix, an antigen, a preservative and a stabilizer; the antigens comprise a cardiac troponin I antigen, a creatine kinase isoenzyme antigen, a myoglobin antigen, an amino-terminal brain natriuretic peptide precursor antigen, a brain natriuretic peptide antigen, a D-dimer antigen, a heart-type fatty acid binding protein antigen, a myeloperoxidase antigen and a lipoprotein phospholipase A2 antigen; the stabilizer comprises at least one of D-trehalose, cane sugar, glycine, inositol and polyethylene glycol. The cardiovascular marker substance control substance disclosed by the invention can cover various cardiovascular disease markers including heart failure, pulmonary artery embolism, vasculitis, atherosclerosis, myocardial injury, myocardial infarction and the like. The quality control product disclosed by the invention can be used as a third-party quality control product for screening cardiovascular diseases and performing indoor and interventricular quality control on an auxiliary diagnosis and measurement system.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The present disclosure relates to stable pharmaceutical compositions comprising fixed dose combination of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of such fixed dose combinations, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The invention discloses functional recombinant soybean protein isolate emulsion gel as well as a preparation method and application thereof, and belongs to the technical field of soybean protein processing. The preparation method comprises the following steps: recombining three main components, namely soybean lipophilic protein, glycinin and beta-conglycinin, in soybean protein isolate (SPI) according to a certain compounding ratio, and carrying out combined modification on the recombined SPI by virtue of modification means such as ultrasonic treatment, heat treatment, magnetic field and enzyme crosslinking; the recombined SPI emulsion is subjected to micronization treatment by adopting high-pressure microjet homogenization treatment, and then the emulsion is jointly induced to be gelatinized by utilizing acid and salt ions and transglutaminase, so that the preparation efficiency, the structural strength and the stability of the emulsion gel are improved; two polyphenols, namely epigallocatechin gallate and quercetin, are co-embedded in an interface and an oil phase of the emulsion gel, so that the bioaccessibility and antioxidant activity of the polyphenols are improved, and the emulsion gel is endowed with functionality. The prepared emulsion gel can be widely applied to processing of functional food.

The invention relates to an apolipoprotein E detection reagent and application thereof, and belongs to the technical field of biomedicine. The invention provides application of a plant derivative in preparation of an APOE epitope exposure agent. The plant derivative is selected from at least one of curcumin, emodin, EF24 and FLLL-32. The invention also provides an APOE epitope exposure agent which comprises a surfactant, salts, a reducing agent and plant derivatives. According to the present invention, the sample and the protein are pre-treated by using the epitope exposure agent containing the plant derivative to improve the sufficiency of the ApoE protein epitope exposure so as to achieve the accurate typing of the ApoE gene based on the immunological detection method and the accurate quantification of the proteins with different genotypes. Genetic typing of ApoE and quantitative detection of proteins with different genotypes are carried out based on an immunological detection method, and the genotype detection result is highly consistent with a fluorescent PCR (Polymerase Chain Reaction) result.

The invention discloses application of breast milk-derived lactobacillus gasseri in reducing weight, reducing blood fat, preventing and treating type 2 diabetes mellitus, relieving intestinal leakage and inhibiting intestinal pathogens, and belongs to the technical field of microorganisms and the technical field of medicines. The invention provides a new application of lactobacillus gasseri in reducing weight, reducing blood fat, preventing and treating type 2 diabetes, relieving intestinal leakage and inhibiting intestinal pathogens. The traditional Chinese medicine composition can effectively prevent weight gain, body fat rate increase, low-density lipoprotein cholesterol and triglyceride increase of mice caused by high-fat diet, inhibit postprandial blood sugar and insulin resistance index increase, inhibit intestinal mucosa damage and growth of intestinal pathogenic bacteria, and effectively improve chronic diseases of mice with high-fat diet. Therefore, the lactobacillus gasseri FN136 has a huge application prospect in preparation of products for reducing weight, reducing blood fat, preventing and treating type 2 diabetes mellitus, relieving intestinal leakage and inhibiting intestinal pathogens.

The invention provides salivary gland apolipoprotein, a gene, a carrier, a recombinant bacterium and application of salivary gland apolipoprotein, and belongs to the technical field of tick prevention and control. The amino acid sequence of the salivary gland apolipoprotein of the ligamentosa is as shown in SEQ ID NO.1. The invention further discloses a preparation method of the salivary gland apolipoprotein. After the salivary gland apolipoprotein provided by the invention is used for immunizing mice, the death rate of infected ticks can be increased, the blood sucking time can be prolonged, and the ecdysis rate of the ticks can be reduced, so that the protein or the gene provided by the invention can be used as a prevention and control target of the ticks, can be used for developing anti-tick vaccines, can be used for preventing and controlling the ticks and tick-borne diseases, and has a profound application prospect.

The invention provides an apolipoprotein B detection kit and a use method thereof, the apolipoprotein B detection kit comprises a reagent R1 and a reagent R2, the reagent R1 comprises the following components: 40-80 mmol / L of an HEPES buffer solution, and 1-5 g / L of polyethylene glycol 6000; naCl is 5 g / L to 9 g / L; the preservative is 1g / L to 5g / L, and the surfactant is 1g / L to 5g / L; the pH value of the reagent R1 is 7.0 to 7.5; the pH value is 7.0-7.5 in the reagent R1, so that the pH value is below the isoelectric point of apolipoprotein B, and after the apolipoprotein B and the reagent R1 are mixed, protein in a detection sample can present weak negative charge property; accordingly, hyaluronic acid is added into the reagent R2, the hyaluronic acid and the anti-human APOB antibody in the reagent can form an integrated substance with weak covalent bond combination, and the hyaluronic acid has positive charges, so that apolipoprotein B can be rapidly combined with the anti-human APOB antibody through the attraction of the charges, the problem of long-time incubation is avoided, and the detection accuracy is improved. The detection time is shortened and the accuracy of the detection result is ensured.

The invention provides an SNP (Single Nucleotide Polymorphism) site for detecting the intramuscular fat content of cattle, the SNP site is located at the 27108th basic group of a cattle EBPL (Epstein-Barr Protein Lipoprotein Lipoprotein) gene and is located at the 19205817 position of a 12 # chromosome, and the genotype of the SNP site is GG, GA or AA. Therefore, the SNP (Single Nucleotide Polymorphism) is named as EBPL g.27108Agt; and G. The invention also provides a KASP detection method for the intramuscular fat content of cattle, which comprises the following steps: extracting DNA (Deoxyribonucleic Acid) of a cattle individual to be detected, then typing an amplified fragment, and judging the intramuscular fat content according to a typing result. The method for detecting the intramuscular fat content of cattle is obtained by researching the correlation between EBPL and the intramuscular fat content, cattle breeding can be facilitated on the basis of the method, a foundation is laid for further increasing the intramuscular fat content of beef and conveniently and rapidly judging the intramuscular fat content of beef, and the method is suitable for large-scale popularization and application. And the method has important significance on the breeding of cattle with excellent meat quality.

Processes for providing a PEGylated protein composition comprising mono-PEGylated protein and oligo-PEGylated protein, and processes for providing mono-PEGylated protein compositions with high yield and productivity are provided. The processes are particularly suitable for providing mono-PEGylated erythropoietin composition. The processes comprise reacting a non-PEGylated protein with a PEGylation reagent to produce a mixture comprising non-PEGylated, mono-PEGylated and oligo-PEGylated protein, subjecting the mixture to a step of anion exchange chromatography, and recycling non-PEGylated protein into further PEGylation reactions.

The present invention relates to an anti-apolipoprotein E4 (ApoE4) antibody and use thereof and, more specifically, to: an anti-ApoE4 antibody or an antigen-binding fragment thereof; a fusion in which the anti-ApoE4 antibody or an antigen-binding fragment thereof and one or more blood-brain barrier (BBB) receptor-binding peptides are bound; a method for preparing the fusion; and a composition for preventing or treating neurodegenerative diseases or metabolic diseases, comprising the anti-ApoE4 antibody or an antigen-binding fragment thereof, or the fusion.

Disclosed herein are synthetic nanoparticles, pharmaceutical compositions, kits, or methods for treating and / or preventing cancer. In some embodiments, the synthetic nanoparticles and / or pharmaceutical compositions comprises a pH sensitive liposome, an apolipoprotein, and andrographolide or derivative thereof. In some embodiments, the synthetic nanoparticles are delivered to a subject for treatment of cancer. In some embodiments, the cancer is T-cell lymphoma or B-cell lymphoma.

An siRNA capable of inhibiting the expression of apolipoprotein C3 (APOC3) gene, comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand are respectively composed of nucleotide sequence I or nucleotide sequence II comprising 19 modified or unmodified nucleotides, and the nucleotide sequence I and the nucleotide sequence II are at least partially reverse complementary to form a double-stranded region, and the nucleotide sequence II is at least partially reverse complementary to a nucleotide sequence segment in the mRNA of APOC3 gene expression; in the direction from the 5'-end to the 3'-end, at least one of the 3-6th nucleotides of the nucleotide sequence II is a stabilized modified nucleotide. The siRNA as described above, as well as the pharmaceutical composition and siRNA conjugate comprising the siRNA, can effectively treat and / or prevent diseases or disorders related to APOC3 gene expression, and have a significantly reduced off-target effect.

A novel genetically modified bacterium is disclosed. The bacterium has one or more anti-spike glycoprotein nanobodies on the outer membrane of the bacterium. In one embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Intimin. In another embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Lpp-OmpA.